


Sphinkterinsuffizienz: Zelltherapie als neuer Hoffnungsträger




Interdisziplinäre Viszerale Chirurgie und Medizin

Okttober 2012

Lukas Brügger


u^b

UNIVERSITÄT
BERN



UVCM

Prevalence of incontinence



Perry S, Gut 2002

Teunissen TA, Int Urogynecol J Pelvic Floor Dysfunct 2004

Johanson JF, Am J Gastroenterol 1996

Economic consequences

~~Direct costs to UK~~

**CH: CHF 12
Million/year!**


~~88.5 million~~



Integrated continence service 2000




International Consultation on Incontinence 2008




International Consultation on Incontinence 2008

Sphincteroplasty




Sphincteroplasty: longtime follow up

N=69





Halverson AL. Dis Colon Rectum 2002




International Consultation on Incontinence 2008

Sacral nerve modulation (SNS)




Stage I




Evaluation
2-3 weeks


Stage II



Follow up
1, 6, 12 weeks...





Sacral spinal nerve stimulation for faecal incontinence: multicenter study



Matzel KE. Lancet 2004

Quality of life



Matzel KE. Lancet 2004

Efficacy of SNS

Author	Year	No. of temporary	Success n (%)	No. of permanent	Success n (%)	Continent n (%)	ITT success n (%)	Follow-up median (months)	ITT continent n (%)	Delphi score
Ripetti et al ¹⁴	2002	21	4 (19)	4	4 (100)	0 (0)	4 (19) ^a	15	0 (0)	2
Rasmussen et al ²⁰	2004	45	37 (82)	37	32 (86)	n/a	32 (71) ^a	6	n/a	1
Conaghan et al ²¹	2005	5	3 (60)	3	3 (100)	2 (67%)	3 (67) ^a	n/a	2 (40)	0
Faucheron et al ²²	2006	40	29 (73)	29	24 (83)	n/a	24 (60) ^a	6	n/a	0
Gourcerol et al ²³	2007	61	35 (57)	33	20 (61)	6 (18)	20 (33) ^a	12	6 (10)	2
Melenhorst et al ²⁴	2007	134	100 (75)	100	79 (79)	n/a	79 (59) ^a	26	n/a	2
Hetzer et al ²⁵	2007	44	37 (84)	37	34 (92)	n/a	34 (77)	13	n/a	3
Holzer et al ²⁶	2007	36	29 (81)	29	28 (97)	n/a	28 (78) ^a	35	n/a	2
Dudding et al ²⁷	2008	70	61 (87)	51	41 (80)	19 (37)	41 (58) ^a	24	19 (27)	0
Gstaltner et al ²⁸	2008	11	5 (45)	5	5 (100)	4 (80)	5 (45) ^a	n/a	4 (36)	2
Muñoz-Duyos et al ²⁹	2008	43	29 (67)	29	25 (86)	14 (48)	25 (58) ^a	35	14 (32)	2
Tjandra et al ³⁰	2008	60	54 (90)	53	38 (72)	22 (42)	38 (63)	12	22 (37)	2
Vitton et al ³¹	2008	5	5 (100)	5	5 (100)	n/a	5 (100)	14	n/a	3
Roman et al ³²	2008	18	18 (100)	18	14 (78)	n/a	14 (78) ^a	3	n/a	1
Boyle et al ³³	2009	15	13 (87)	13	10 (77)	6 (40)	10 (66)	n/a	6 (40)	3
Altomare et al ³⁴	2009	94	60 (64)	60	37 (61)	9 (15)	37 (39) ^a	74	9 (10)	0
Vallet et al ³⁵	2010	45	32 (71)	32	23 (72)	9 (28)	23 (51)	44	9 (20)	3
Michelsen et al ³⁶	2010	167	132 (79)	126	91 (72)	n/a	91 (54)	24	n/a	1
Wexner et al ³⁷	2010	133	120 (90)	106	88 (83)	43 (41)	88 (66)	12	43 (32)	3


SNS = sacral nerve stimulation; ITT = intention to treat; n/a = not available.

^aDenotes studies where ITT was calculated from presented data.


83(61-100)%
40(0-80)%
60(19-100)%
32(0-40)%

Boyle DCR 2011


Is a morphologically intact sphincter necessary?



Melenhorst J. Colorectal Dis 2007




International Consultation on Incontinence 2008




International Consultation on Incontinence 2008

Acticon™ Neosphincter*



Scott Urology 1973

Dynamic graciloplasty (DGP)



Acticon™ Neosphincter: Results

Table 2. Summary of raw data from the 20 most recent relevant studies on artificial bowel sphincter (ABS) (March 2005)

First author ^{Ref}	Year	No. of patients	Mean age (years)	Follow-up (years)	Success rate	Surgical revisions	Explantations (total)	Complications (total)	Level of evidence
Da Silva ²⁰	2004	11	25.3	1.7	8	1	0	5	III
Altomare ³⁷	2004	28	58.0	4.2	6	14	11	47	IV
Casal ³⁸	2004	10	56.0	2.4	2	4	3	7	IV
O'Brien ¹⁵	2004	7	66.0	0.5	6	3	1	5	II
Ortiz ²⁴	2003	8	34.4	3.7	2	5	3	10	III
Michot ⁸	2003	25	51.1	2.8	12	8	5	10	IV
Parker ¹⁶	2003	47	39.5	5.4	12	25	22	47	IV
Romano ³⁹	2003	8	52.6	1.4	5	0	0	5	IV
Devesa ⁴⁰	2002	53	46.0	2.2	13	16	14	77	IV
Lehur ⁴¹	2002	16	43.0	2.1	11	2	5	7	IV
Wong ¹⁴	2002	115	49.0	1.0	51	81	41	454	IV
Ortiz ⁴²	2002	22	47.0	2.3	4	6	9	17	IV
Lehur ⁴³	2000	24	44.0	1.7	18	9	8	14	IV
Dodi ⁴⁴	2000	8	n.a.	0.9	6	0	2	4	IV
O'Brien ¹⁸	2000	13	44.0	n.a.	9	4	3	8	IV
Christiansen ⁴⁵	1999	17	46.0	7.0	8	6	7	5	IV
Lehur ¹³	1998	13	40.0	2.5	4	8	4	9	IV
Vaizey ⁴⁶	1998	6	53.0	0.8	2	1	1	9	IV
Gelet ⁴⁷	1997	1	61.0	2.0	1	2	0	2	IV
Wong ⁶	1996	12	33.0	4.8	9	7	7	4	IV
Total		444	46.8	2.6	189 (42.6%)	202 (45.5%)	146 (33%)	746 (168%)	Lowest level of evidence

n.a., not available

^aOnly ABS arm of patients

Belyaev Surg Today 2006

Dynamic graciloplasty: Results

Table 1. Summary of raw data from the 20 most recent relevant studies on dynamic graciloplasty (DGP) (March 2005)

First author ^{Ref.}	Year	No. of patients	Mean age (years)	Follow-up (years)	Success rate	Surgical revisions	Explantations (total)	Complications (total)	Level of evidence
Koch ¹⁹	2004	28	25.0	4.0	10	15	9	32	IV
Da Silva ^{a20}	2004	5	25.3	1.7	1	2	0	3	III
Penninckx ¹²	2004	60	43.0	4.4	37	61	27	75	IV
Thornton ²¹	2004	38	62.0	5.0	2	15	12	17	IV
Violi ²²	2004	23	64.3	4.7	13	12	2	32	IV
Rongen ²³	2003	200	48.0	5.0	145	7	46	138	IV
Ortiz ^{a24}	2003	8	43.6	3.3	0	5	4	9	III
Wexner ²⁵	2002	115	50.3	2.0	15	n.a.	66	n.a.	IV
Konsten ²⁶	2001	81	43.0	n.a.	46	21	35	35	IV
Rullier ²⁷	2000	15	54.0	2.3	7	8	1	16	IV
Baeten ²⁸	2000	123	50.0	1.9	55	170	n.a.	189	IV
Mander ²⁹	1999	64	44.5	1.3	29	10	27	44	IV
Rouanet ³⁰	1999	9	51.2	2.7	5	3	1	n.a.	IV
Violi ³¹	1999	13	61.0	1.5	4	4	n.a.	4	IV
Cavina ³²	1998	31	58.0	3.2	22	7	6	9	IV
Rosen ³³	1998	28	53.5	1.0	19	9	5	14	IV
Geerdes ³⁴	1997	20	52.0	2.0	8	5	5	n.a.	IV
Altomare ³⁵	1997	9	45.0	2.0	4	9	4	14	IV
Mander ³⁶	1996	12	59.3	1.0	0	8	2	12	IV
Baeten ¹¹	1995	52	44.0	2.1	38	7	7	11	IV
Total		934	48.6	2.7	460 (49.3%)	378 ^b (46.2%)	259 ^c (32.5%)	654 ^d (82.8%)	Lowest level of evidence

^aOnly DGP arm of patients

^b378 revisions in 819 patients


^c259 explantations in 798 patients


^d654 complications in 790 patients

n.a., not available

Belyaev Surg Today 2006

Background





International Consultation on Incontinence 2008